Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
On 06/18/2025, Entrada Therapeutics (TRDA) filed a Form 4/A amending its prior insider-trading report. The filing discloses that director Peter S. Kim bought an additional 25,000 common shares on 05/13/2024 at a weighted-average price of $14.6804. This transaction was omitted from the original Form 4 filed on 05/16/2024, which had already reported a separate 25,000-share purchase on 05/14/2024 at $14.5869.
After including both purchases, Kim now directly owns 117,412 TRDA shares. No derivative securities were reported. The amendment corrects share totals and indicates that the director accumulated 50,000 shares over two consecutive trading days, a potential sign of insider confidence despite the minor reporting lapse.